Medicaid “Best Price” Should Guide Medicare ASP Calculations, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers may make “reasonable assumptions” based upon their business practices in the Medicaid program when calculating average sales price for Part B drugs. Companies should include such assumptions with their ASP data submissions, due April 30.
You may also be interested in...
Average Sales Price Disclosures Can Open Communication With CMS, Attorney Says
ASP reporting regulations “create significant issues and hurdles” for manufacturers, Mintz Levin attorney Carolyn McElroy says. House Energy & Commerce Committee Counsel says federal enforcers are “sympathetic” to manufacturers’ uncertainty about ASP reporting.
Average Sales Price Formula Closely Follows Medicare Rx Law
The ASP final rule is scheduled to be published in the Federal Register April 6. CMS notes that the methodology may change in future years to include further price concessions.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.